CVTX CV Therapeutics (MM)

CV Therapeutics Appoints Thomas E. Shenk, Ph.D. to Board of Directors PALO ALTO, Calif., Dec. 16 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (NASDAQ:CVTX) today announced that it has appointed Thomas E. Shenk, Ph.D., to the company's board of directors. Dr. Shenk, Elkins Professor in the department of molecular biology at Princeton University, currently serves on the boards of directors of Merck & Co., Inc. and of Cell Genesys, Inc. Dr. Shenk is a world renowned expert in virology and the immediate past president of the American Society for Microbiology. He is also a member of the National Academy of Sciences and of the Institute of Medicine, has published more than 200 scientific papers and holds multiple patents. Dr. Shenk received his Ph.D. in microbiology from Rutgers University and trained as a postdoctoral fellow at Stanford University. "Tom's broad knowledge of the pharmaceutical industry and his world class scientific expertise will prove valuable in helping CV Therapeutics to achieve our goal of moving multiple potential product candidates through the drug development process and into the commercial marketplace," said Louis G. Lange, M.D., Ph.D., chairman and chief executive officer of CV Therapeutics. About CV Therapeutics CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics has entered into an agreement with Solvay Pharmaceuticals to co-promote ACEON(R) (perindopril erbumine) Tablets for the treatment of hypertension, and CV Therapeutics currently has four clinical development drug candidates. CV Therapeutics has received an approvable letter from the U.S. Food and Drug Administration (FDA) relating to its new drug application for Ranexa(TM) (ranolazine) for the potential treatment of chronic angina, and has submitted an application for the approval of ranolazine for the potential treatment of chronic angina to the European Medicines Agency. Regadenoson is a selective A2A-adenosine receptor agonist for potential use as a pharmacologic stress agent in cardiac perfusion imaging studies. Tecadenoson is a selective A1- adenosine receptor agonist for the potential reduction of rapid heart rate during atrial arrhythmias. Adentri(TM) is a selective A1-adenosine receptor antagonist for the potential treatment of heart failure and has been licensed to Biogen Idec Inc. For more information, please visit CV Therapeutics' website at http://www.cvt.com/. Ranexa, regadenoson, tecadenoson and Adentri have not been approved for marketing by the FDA or any foreign regulatory authorities. These products are currently under investigation in clinical trials subject to United States Investigational New Drug applications, and as applicable, appropriate clinical trial applications to regulatory authorities outside the United States. Except for the historical information contained herein, the matters set forth in this press release, including statements as to development, clinical studies, regulatory review, and commercialization of products, are forward- looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including, early stage of development; regulatory review and approval of our products; the conduct and timing of clinical trials; the dependence on collaborative and licensing agreements; commercialization of products; and other risks detailed from time to time in CVT's SEC reports, including its most recent Annual Report on Form 10-K, and its most recent Quarterly Report on Form 10-Q. CVT disclaims any intent or obligation to update these forward-looking statements. DATASOURCE: CV Therapeutics, Inc. CONTACT: Investors: Christopher Chai, Treasurer & Executive Director, Investor Relations, +1-650-384-8560, or Media: John Bluth, Senior Director, Corporate Communications, +1-650-384-8850, both of CV Therapeutics, Inc. Web site: http://www.cvt.com/

Copyright